Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study

Moran Livne-Margolin*, Daniel Ling, Shani Attia-Konyo, Chaya Mushka Abitbol, Ola Haj-Natour, Bella Ungar, Shomron Ben-Horin, Uri Kopylov

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Extraintestinal manifestations (EIM) are associated with diminished quality of life. The efficacy of Ustekinumab and vedolizumab for EIM treatment is not well established. The aim was to compare the effectiveness of ustekinumab and vedolizumab for treatment of EIM in IBD. Methods: We included IBD patients treated with vedolizumab or ustekinumab in the Gastroenterology department, Sheba Medical Center, for up to 52 weeks between 2015 and 2021. Patients with active EIM before treatment initiation were included. Results: 111 patients were included. 53 patients (48%) were treated with ustekinumab; 88% (n-99) had CD. The most common EIM was arthralgia (95/111, 84%). Patients treated with ustekinumab were more likely to be anti-TNF experienced (n-51/53 [96%] compared with vedolizumab n = 36/58 [62%], p < 0.001). Clinical response of EIM at week 52 was achieved in 36% of patients treated with ustekinumab (n-18/50) and 34% of patients (n-19/54) treated with vedolizumab, with no statistically significant difference (p = 0.9). No statistical significance was achieved for patients presented with arthralgia. Clinical response of arthralgia at week 52 was seen in 34% (n-19/55) and 36% (n-18/46) of the patients treated with vedolizumab and ustekinumab, respectively, (p = 0.3). Conclusion: In this study, no difference was found between vedolizumab and ustekinumab regarding their effect on EIM in IBD patients for up to 52 weeks.

Original languageEnglish
Pages (from-to)223-229
Number of pages7
JournalDigestive and Liver Disease
Volume55
Issue number2
DOIs
StatePublished - Feb 2023

Funding

FundersFunder number
Medtronic
AbbVie
Meso Scale Diagnostics
Takeda Pharmaceutical Company
Janssen Pharmaceuticals

    Keywords

    • Biologic therapy
    • Extra intestinal manifestation
    • Inflammatory bowel disease
    • Ustekinumab
    • Vedolizumab

    Fingerprint

    Dive into the research topics of 'Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study'. Together they form a unique fingerprint.

    Cite this